Filtered By:
Drug: Angiomax

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
ConclusionIn patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - October 28, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Femoral vascular closure device use, bivalirudin anticoagulation and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
Conclusion: In patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - September 1, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Original Studie Source Type: research

Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry.
Conclusions: Bivalirudin usage in the setting of primary PCI provided excellent results in terms of 30-day outcome even in a real-world population. PMID: 25101656 [PubMed - as supplied by publisher]
Source: Acute Cardiac Care - August 7, 2014 Category: Cardiology Authors: Limbruno U, Picchi A, Galli S, Huber K, Lipiecki J, Bernstein D, Deliargyris E, Anthopoulos P, Nienaber C, Hamon M Tags: Acute Card Care Source Type: research

Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
Conclusion: In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Martial Hamon, Christopher A. Nienaber, Stefano Galli, Kurt Huber, Janusz Lipiecki, Jonathan M. Hill, Nicolas Amabile, Debra Bernstein, Efthymios Deliargyris, Antoine Lafont, Philippe Gabriel Steg Tags: Original Articles Source Type: research

Bivalirudin use and one‐month outcome in the context of contemporary antiplatelet treatment: Insights from the Greek Antiplatelet Registry
ConclusionsIn a ‘real life’, contemporary antiplatelet treatment registry, clinical, laboratory and logistic factors affect bivalirudin's choice, while there are no differences in one‐month outcome between bivalirudin and no bivalirudin treated patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2014 Category: Cardiology Authors: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Spyridon Deftereos, George Sitafidis, Ioannis Kanakakis, Michalis Hamilos, George Karayannis, Christos Angelidis, Katerina Stavrou, Manolis Vavuranakis, John A. Goudevenos, Christodoulos Stefanadis, Tags: Original Research Article Source Type: research

Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involving the e...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
In conclusion, in patients with STEMI who underwent primary PCI of LAD, the use of bivalirudin was associated with a reduction in mortality and bleeding rates at 3 years. PES reduced revascularization rates in this population but did not have a significant impact on mortality.
Source: The American Journal of Cardiology - June 10, 2013 Category: Cardiology Authors: Jochen Wöhrle, Bruce Brodie, Bernhard Witzenbichler, Dariusz Dudek, Ran Kornowski, Chris Metzger, Cindy Grines, Thomas C. McAndrew, Helen Parise, Ziad Sergie, Roxana Mehran, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR Peripheral Vascular Disease
Conclusions— Bivalirudin was associated with lower rates of hemorrhagic outcomes compared with UFH during the index hospitalization for carotid artery stenting. In-hospital and 30-day ischemic events were similar between the 2 groups. Randomized comparisons of these agents are needed to confirm these findings.
Source: Circulation: Cardiovascular Interventions - April 16, 2013 Category: Cardiology Authors: Wayangankar, S. A., Abu-Fadel, M. S., Aronow, H. D., Kennedy, K. F., Gupta, R., Yeh, R. W., Gray, W. A., Rosenfield, K., Hennebry, T. A. Tags: Heparin, Other anticoagulants, Carotid Stenosis, Angioplasty and Stenting, Transient Ischemic Attacks Peripheral Vascular Disease Source Type: research